loading...| Preferred Name | dabrafenib | |
| Synonyms |
N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide C23H20F3N5O2S2 dabrafenib |
|
| ID |
http://purl.obolibrary.org/obo/CHEBI_75045 |
|
| AHFScode |
10:00 |
|
| ATCCode |
L01XE23 |
|
| binds |
http://purl.obolibrary.org/obo/dinto_1576 http://purl.obolibrary.org/obo/dinto_1577 http://purl.obolibrary.org/obo/dinto_1975 http://purl.obolibrary.org/obo/dinto_0899 http://purl.obolibrary.org/obo/dinto_0883 http://purl.obolibrary.org/obo/dinto_1568 http://purl.obolibrary.org/obo/dinto_2019 http://purl.obolibrary.org/obo/dinto_1824 http://purl.obolibrary.org/obo/dinto_3974 http://purl.obolibrary.org/obo/dinto_0520 http://purl.obolibrary.org/obo/dinto_0901 |
|
| DBBrand |
tafinlar |
|
| DBSalt |
dabrafenib mesylate |
|
| DBSynonym |
gsk2118436 |
|
| Definition |
An organofluorine compound and antineoplastic agent, used as its mesylate salt in treatment of metastatic melanoma. Dabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013. |
|
| has pharmacological target | ||
| has role | ||
| InChI |
InChI=1/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29) InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29) |
|
| InChIKey |
InChIKey=BFSMGDJOXZAERB-UHFFFAOYNA-N InChIKey=BFSMGDJOXZAERB-UHFFFAOYSA-N |
|
| induces | ||
| inhibits |
http://purl.obolibrary.org/obo/dinto_1576 http://purl.obolibrary.org/obo/dinto_1577 http://purl.obolibrary.org/obo/dinto_1975 http://purl.obolibrary.org/obo/dinto_0899 http://purl.obolibrary.org/obo/dinto_0883 http://purl.obolibrary.org/obo/dinto_1568 http://purl.obolibrary.org/obo/dinto_2019 http://purl.obolibrary.org/obo/dinto_1824 |
|
| is metabolised by | ||
| is substrate of |
http://purl.obolibrary.org/obo/dinto_0901 http://purl.obolibrary.org/obo/dinto_1221 |
|
| is transported by | ||
| label |
dabrafenib |
|
| may interact with |
http://purl.obolibrary.org/obo/dinto_DB00683 http://purl.obolibrary.org/obo/CHEBI_5296 http://purl.obolibrary.org/obo/CHEBI_8107 http://purl.obolibrary.org/obo/CHEBI_8069 http://purl.obolibrary.org/obo/CHEBI_8776 http://purl.obolibrary.org/obo/CHEBI_7494 http://purl.obolibrary.org/obo/CHEBI_3387 http://purl.obolibrary.org/obo/CHEBI_3732 http://purl.obolibrary.org/obo/CHEBI_7915 |
|
| prefixIRI |
obo2:CHEBI_75045 |
|
| prefLabel |
dabrafenib |
|
| SMILES |
CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1 CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)-c1ccnc(N)n1 |
|
| Synonym |
N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide C23H20F3N5O2S2 dabrafenib |
|
| xref |
CiteXplore:23714462 CiteXplore:23833299 CiteXplore:23537694 CiteXplore:23470635 CiteXplore:23249624 CiteXplore:23463215 CiteXplore:23237741 CiteXplore:23870055 Reaxys:19689971 Patent:WO2011047238 Wikipedia:http://en.wikipedia.org/wiki/Dabrafenib CiteXplore:23290787 CiteXplore:23403819 CiteXplore:23844038 CiteXplore:23795808 RxList:http://www.rxlist.com/tafinlar-drug.htm KEGG DRUG:D10064 CiteXplore:23552670 CiteXplore:23846776 National Drug Code Directory:0173-0847-08 CiteXplore:23317446 ChEMBL:1440894 Drugs.com:http://www.drugs.com/tafinlar.html CiteXplore:22981500 CiteXplore:23656699 CiteXplore:23881668 CiteXplore:23617957 CiteXplore:23515890 CiteXplore:23621583 CiteXplore:23709751 CiteXplore:23276366 CiteXplore:23608920 CASRN:1195765-45-7 CiteXplore:23807941 Wikipedia:Dabrafenib |
|
| subClassOf |